

## Completion of Tranche 1 of Placement and Cleansing Notice

**PERTH, Australia, 15 September 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, advises the completion of Tranche 1 of the share placement raising approximately A\$60 million (before costs), priced at \$2.05 per share (the “Placement”) as announced to ASX on 9 September 2025.

For further details of the A\$75 million two tranche Placement, including use of funds, refer to the announcement and Appendix 3B lodged with ASX on 9 September 2025.

A total of 29,409,778 ordinary fully paid shares were issued to professional and sophisticated investors pursuant to the Company's 15% placement capacity under ASX Listing Rule 7.1 and 10% additional capacity under ASX Listing Rule 7.1A.

Tranche 2 of the Placement, to raise approximately A\$15 million (before costs), is subject to shareholder approval at a general meeting to be held in October.

A cleansing notice is attached to this announcement regarding the issue of the abovementioned securities.

### Share Purchase Plan (SPP)

As advised on 9 September 2025, eligible Artrya shareholders, on the record date, being 8 September 2025, will also be provided the opportunity to subscribe for additional shares in the Company at A\$2.05 per share, being the same price as the Placement. Eligible shareholders will be entitled to subscribe for up to A\$30,000 worth of new shares

The SPP will open on 15 September 2025 and close on 3 October 2025, with new shares under the SPP expected to be issued on or before 10 October 2025. This timing is indicative only and may be subject to change at the discretion of the Company and in compliance with the ASX Listing Rules and Corporations Act.

**- Ends -**

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### **About Artrya**

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

## For more information:

### Corporate Enquiries

**John Konstantopoulos**

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

**David Allen or John Granger**

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

15 September 2025

The Manager  
Company Announcements Office  
ASX Limited  
Level 6, 20 Bridge Street  
SYDNEY NSW 2000

**CLEANSING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT**

On 15 September 2025, Artrya Limited (Company) completed the tranche one issue, by way of placement, of 29,409,778 fully paid ordinary shares in the capital of the Company (Shares) at an issue price of \$2.05 per Share to sophisticated and professional investors (Placement). The two tranche Placement was previously announced on 9 September 2025.

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) section 674 and section 674A of the Corporations Act; and
3. as at the date of this notice, there is no information that is "excluded information" (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with Section 708A(8) of the Corporations Act.

This announcement is authorised for release by the Board of Artrya Limited.

Yours Sincerely,



Kevin Hart  
Company Secretary